The medical device developer has moved into Liverpool’s newly opened CENTRAL TECH, to progress its pre-commercialisation R&D.
Sepsiscan, a University of Latvia spinout, has this month established its first overseas base, choosing to locate within Sciontec-owned CENTRAL TECH innovation centre, in Liverpool.
The bold move will enable Sepsiscan to further develop its AI-powered, medical imaging device, which is used for real-time evaluation of early sepsis diagnostics, as well as to engage with new R&D partners.
Didzis Rutitis, Dr.sc.administr, CEO of Sepsiscan, said:
“Sepsis is a major global health concern affecting around 49 million people every year. By improving early recognition and diagnosis of sepsis through our AI and machine learning powered solution, we’re making a significantly positive impact on public health and are saving lives worldwide.”
“Thanks to a number of invaluable conversations in recent years with the Department for Business & Trade in Latvia, the UK’s National Institute for Health and Care Research, and most recently with Liverpool City Region Combined Authority, we have been able to realise our global ambitions more quickly than initially anticipated.”
Born out of a 2016 research project within the University of Latvia, the medical screening and triage tool progressed from its initial prototyping phase in 2022, to becoming an asset of an IP licensed spin-out in 2023. The following three years saw further technical development, live trials and several investment rounds take place within the business, culminating in Sepsiscan’s registration with Companies House in the UK in January 2026.
The MedTech company has grown to a team of seven, including clinicians, software engineers, and product developers. Sepsiscan also has several international research partners and has agreed on future collaborations for validation of its technology within shared research activities.
Didzis Rutitis, Dr.sc.administr, added:
“Ahead of officially launching our novel product within the EU and UK markets, we wanted to establish a new international base, which already has a good cluster of leading healthcare players nearby, as well as having a collaborative stakeholder ethos, strong transport links, and an element of rich history and culture.
“We’re delighted to have found all of this in abundance in Liverpool, and specifically love the city’s knowledge cluster and innovation ecosystem.”
Sepsiscan’s new workspace at CENTRAL TECH, in the heart of the Knowledge Quarter Liverpool (KQ Liverpool) innovation district, places it among many of the region’s principal healthcare organisations, including Royal Liverpool University Hospital, Liverpool School of Tropical Medicine, Clatterbridge Cancer Centre, and the Royal College of Physicians, in addition to multiple technology, digital and life sciences focused SMEs at CENTRAL TECH, Liverpool Science Park, and Sciontec AI at The Spine.
A further benefit to Sepsiscan is involvement within KQ Liverpool’s new business support programme, KQ CLICK. They have already taken advantage of direct introductions to local experts specialising in patent asset protection, investment and commercialisation, which will ensure a more streamlined and risk-free landing in Liverpool.
To find out more about Sepsiscan, please visit their website.
